-

01:47:50 PM

LIVE Real Time CYDY Stock Market News

CYDY - CYDY

04/22/21 11:52 PM

OTC : CYDY

CytoDyn Completes $28.5 Million Convertible Note Financing with Conversion Rate at $10.00 Per Share Without Warrants

CytoDyn Inc. (OTC.QB: CYDY), ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab (Vyrologix or PRO 140), a CCR5 antagonist with the potential for

RHEA-AI

very positive

04/19/21 6:05 AM

OTC : CYDY

CytoDyn Submits First and Most Crucial Section (CMC) of Interim Order Application to Health Canada for COVID-19 Under Rolling Review

CytoDyn Inc. (OTC.QB: CYDY),

RHEA-AI

neutral

04/19/21 6:00 AM

OTC : CYDY

Former President of the Philippines, Joseph Estrada, Among the Many COVID-19 Patients Receiving Leronlimab Under CSP in the Philippines

CytoDyn Inc. (OTC.QB: CYDY), ("CytoDyn" or the "Company"), a late-stage biotechnology

RHEA-AI

neutral

04/15/21 9:26 AM

OTC : CYDY

CytoDyn Executes Exclusive Supply and Distribution Agreement with Chiral Pharma Corporation to Provide Up to 200,000 vials of Leronlimab to Philippines

CytoDyn Inc. (OTC.QB: CYDY), ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab (PRO

RHEA-AI

neutral

04/08/21 5:41 PM

OTC : CYDY

CytoDyn's COVID-19 Long-Hauler's Trial Closed as Enrollment Exceeds Goals

CytoDyn Inc. (OTC.QB: CYDY), ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with potential multiple therapeutic indications, announced today its COVID-19 long-haulers

RHEA-AI

neutral

04/07/21 4:01 PM

OTC : CYDY

CytoDyn Providing Leronlimab to a Philippine Hospital for 28 More COVID-19 Patients under Compassionate Special Permit (CSP)

CytoDyn Inc. (OTC.QB: CYDY), ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab (PRO

RHEA-AI

neutral

04/07/21 6:00 AM

OTC : CYDY

CytoDyn Signs Exclusive Supply and Distribution Agreement with Biomm S.A. in Brazil for COVID-19 and All Other Leronlimab Indications

CytoDyn Inc. (OTC.QB: CYDY), ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with potential multiple therapeutic indications, announced today it has executed an exclusive

RHEA-AI

positive

04/05/21 4:29 PM

OTC : CYDY

CytoDyn Reschedules Webcast from April 6 to April 7

CytoDyn Inc. (OTC.QB: CYDY), ("CytoDyn" or the "Company"), a late-stage biotechnology company developing Vyrologix(TM) (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader

RHEA-AI

neutral

04/05/21 6:05 AM

OTC : CYDY

CytoDyn Completes $28.5 Million Convertible Note Financing with Conversion Rate at $10.00 Per Share Without Warrants to Accelerate Manufacturing of Leronlimab Inventory

CytoDyn Inc. (OTC.QB: CYDY), ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today it completed an

RHEA-AI

neutral

04/05/21 6:00 AM

OTC : CYDY

First Compassionate Special Permit (CSP) Patient in Philippines Improved Significantly 35 hours After First Injection of Leronlimab and Released 3 Days Later

CytoDyn Inc. (OTC.QB: CYDY), ("CytoDyn" or the "Company"), a late-stage biotechnology company developing Vyrologix(TM) (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the

RHEA-AI

neutral